Flushing refers to the temporary or persistent redness of the skin on the face and neck. It occurs due to vasodilation and is known to arise from various causes, such as hormonal changes, sudden temperature fluctuations, inflammatory skin diseases, and prolonged laser treatments.
While laser and hormone therapies are common treatments for flushing, PharmaResearch(CEO Kim Thinkyou, Kang Ki-seok) has recently introduced its skin booster, ‘REJURAN®,’ as an alternative treatment.
‘REJURAN®’ is a medical device designed to temporarily improve facial wrinkles, manufactured using PharmaResearch’s proprietary DOT™ (DNA Optimizing Technology) PN.
According to the paper ‘Current Practices and Perceived Effectiveness of Polynucleotides for Treatment of Flushing by Cosmetic Physicians,’ co-authored by Dr. Oh Seung-min from Gangnam ON Clinic and Professor Shin Dong-wook from the Department of Family Medicine at Samsung Medical Center, PN is used by Korean medical professionals to treat flushing.
A survey conducted among 577 physicians from the Korean Association for Laser Dermatology and Trichology for assessing the status of PN use and awareness of its effects revealed that 84.4% of respondents used PN for flushing caused by dermatitis, 66.4% for flushing resulting from repeated laser treatments or procedures, and 47.4% for flushing due to steroid overuse.
Moreover, 88.1% (470 respondents) evaluated PN as ‘very effective’ or ‘effective’ in these cases, noting its benefits in wound healing and regeneration, skin barrier protection, hydration, vascular stabilization, and anti-inflammation.
Dr. Oh Seung-min, who presented the paper, stated, “This study demonstrates that PN can be an effective alternative for treating flushing,” adding, “It will serve as an important foundational resource for future research and clinical trials on the clinical efficacy of PN.”
A representative from PharmaResearch remarked, “We are highly encouraged to have our key ingredient’s excellence verified through a reputable international academic journal,” and emphasized, “We will continue to establish academic evidence to prove the efficacy of REJURAN.”
Meanwhile, this research paper was published in the SCIE-level international journal ‘Skin Research & Technology.’
Media Contact
Company Name: PharmaResearch
Contact Person: Seohee Han
Email: Send Email
Country: South Korea
Website: http://pharmaresearch.co.kr/en
